Find a Clinical Trial

EA3191

EA3191 - A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

18-79

Learn more

EAQ202

EAQ202, Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

18-39

Learn more

Remodel-2

Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis

18-55

Learn more

Lung CA Dental

Evaluating periodontal health in subjects with lung cancer prior to cancer therapy and monitoring impact of periodontal disease on treatment efficacy and side-effects.

45+

Learn more

HER2 Negative Breast Cancer

HCRN-BRE20-468 - A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

18+

Learn more

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

IMGN857-0421, Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)

18+

Learn more

Multi-spectral imaging

Label-free, multi-scale imaging for improved detection of ovarian cancer metastases

18-99

Learn more

Decartes-08 for Myasthenia Gravis

OGOUS T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
DIRECTED TO B-CELL MATURATION ANTIGEN (BCMA) IN PATIENTS
WITH GENERALIZED MYASTHENIA GRAVIS (MG)

18+

Learn more

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

18+

Learn more

PBCAR0191

Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

18+

Learn more